ScholarIQanswers from OpenAlex

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy

PaperCitations, authors & open-access status

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy have?

ScholarIQcitation count

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy has 345 citations in the OpenAlex counts ScholarIQ stores.

When was Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy published?

ScholarIQyear

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy has 2020 year in the ScholarIQ index.

What is the open-access status of Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy?

ScholarIQoa status

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy has hybrid oa status in the ScholarIQ index.

What is the DOI of Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy?

ScholarIQdoi

The DOI for Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy is on the source record.

What is the PMID of Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy?

ScholarIQpmid

The PMID for Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy is on the source record.

What is the OpenAlex record for Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy?

ScholarIQopenalex

The OpenAlex for Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial